Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine /醫學院
  3. Institute of Medicine/醫學研究所
  4. 影響大腸直腸癌預後相關因子之探討
 
  • Details
Options

影響大腸直腸癌預後相關因子之探討

Date Issued
2022
Author(s)
林庭熏
Ting-Hsun Lin
Advisor
曾淑玲
Shu-Ling Tzeng  
URI
https://handle.ncl.edu.tw/11296/9kyaw7
https://scholars.csmu.edu.tw/handle/123456789/36641
Abstract
不論是在國內外,大腸直腸癌 (Colorectal cancer, CRC)的發生率皆為所有癌別中的前三名。而癌細胞的特殊代謝途徑-Warburg effect,將促使大量的葡萄糖被送入細胞內進行無氧糖解,此途徑的中間產物乳酸去氫酶及最終產物乳酸將隨之增加;藉由癌細胞代謝的角度延伸,進一步探討CRC患者在臨床端之糖類代謝相關的臨床生化數據:空腹血糖 (Glucose AC)、糖化血色素 (HbA1c)、乳酸去氫酶 (LDH)和乳酸 (Lactate)和血液腫瘤指數: 癌胚抗原(CEA)、碳水化合物抗原(CA19-9)與預後之相關性。本研究屬回溯性的世代研究,自中部某醫學中心癌症登記資料庫中納入2011至2015年間初次診斷為CRC的個案共2,168位,再依據病理分期分為0-IV期五個組別;以5年整體存活期 (Overal survival ,OS)作為預後因子,分析各變項數值分布之不同和預後因子之相關性。研究結果:Glucose AC於治療前的數據,在第II、III期族群中的存活分析皆顯示,分布於正常組別相較於血糖偏高組和異常組有著較佳的存活期 (p<0.001;p=0.002)且死亡風險分析上,異常組相較於正常組,有著較高的風險 (p=0.001;p=0.001);HbA1c於治療前的數據,在第IV期族群中的存活分析顯示,分布於正常組的組別有著較佳的存活期 (p=0.031);LDH於治療前的數據,在第IV期族群中的存活曲線分析顯示,分布在正常組別有著較佳的存活期 (p=0.005),死亡風險分析上,分布在異常組別有著較高的風險 (p=0.005);此外,LDH在治療後的數據於第I期族群中,存活分析上也看到了相同的結果 (p=0.025),但死亡風險上則無顯著相關。治療前/後的血液腫瘤指數 CEA和CA19-9 在大部分的期別中都有看到暴露組和OS的顯著性,其中CA19-9更是在第I期的族群中看到了顯著的相關性,此部分CEA則未發現。結論: CRC病患於治療前之糖類代謝相關臨床生化數據,是一項值得臨床在評估預後上的獨立參考指標;於治療前/後的血液腫瘤指數中,CA19-9比CEA更適用於早期期別的族群中。
Whether at Taiwan and abroad, the incidence of colorectal cancer (CRC)is among the top three cancers. The specific metabolism pathway of cancer cell- Warburg effect will promote a large amount of glucose to be sent into the cells for anaerobic glycolysis. The intermediate product of this pathway, lactate dehydrogenase and the final product- lactic acid, will increase accordingly. Through the perspective of cancer cell metabolism, the clinical biochemical data related to CRC patients’ sugar metabolism at the clinical end are further explored: fasting blood glucose (Glucose AC), glycated hemoglobin (HbA1c), lactate dehydrogenase (LDH) and lactic acid (lactate) and the correlation of blood tumor biomarker: cancer embryo antigen (CEA), carbohydrate antigen (CA19-9) and prognosis.This study is a retrospective cohort study. From the cancer registration database of a medical center in central Taiwan, a total of 2,168 cases were first diagnosed as CRC from 2011 to 2015 then those patients were devided into 5 cohorts of phases 0-IV according to the pathological stages. Taking the 5-year overall survival (OS) as the prognosis factor, the difference in the numerical distribution of each variable and the correlation between the prognosis factor is analyzed. Pre-treatment data for Glucose AC, and survival analysis in both Phase II and III cohorts showed that distribution in the < 100 mg/dL group compared to 100-125 mg/dL and > 125 mg/dL group had better survival rate (p<0.001; p=0.002). In the risk analysis of mortality, the >125 mg/dL group had a higher risk than the <100 mg/dL group (p=0.001; p=0.001). The data of HbA1c before treatment in the survival analysis in the IV cohort showed that the group had better survival rate (p=0.031). the pre-treatment data of LDH in the fourth stage Survival curve analysis in the phase IV cohort showed that the group ≤ 192 IU/L had better survival rate (p=0.005). As to the death risk analysis, the group > 192 IU/L had a higher risk (p=0.005). Additionally, the post-treatment data of LDH in the phase I cohort also observed the same results in the survival analysis (p=0.025), but there was no significant correlation with death. We can see the blood tumor biomarker CEA and CA19-9 pre/post-treatment were significantly correlated with the exposure group and OS in most of the phases, and CA19-9 was even more significant in the phase I cohort4 and the significances of CEA are not found. CONCLUSION: The pre-treatment clinical biochemical data with regards to carbohydrate metabolism in CRC patients is a valuable independent reference in clinical evaluation of prognosis. As to the blood tumor biomarker for pre/post treatment, CA19-9 is more feasible for early phase than CEA.
Subjects
大腸直腸癌
糖類代謝
血液腫瘤指數
回溯型世代研究
Colorectal cancer
Glucose
CEA
CA19-9
retrospective cohort study
Type
thesis
File(s)
No Thumbnail Available
Name

110CSMU5534007-001.pdf

Size

54.3 MB

Format

Adobe PDF

Checksum

(MD5):db9a412cda30950d9a3de2061bfa0c48

Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback